A combination of anti-CTLA-4 with anti-PD-1/PD-L1 was found to demonstrate a synergistic effect in melanoma, RCC, and mCRC patients with MMR/MSI-H [53]. This evidence concerns the gene PDCD1 and renal cell carcinoma.